Interleukin-2 receptor-targeted fusion protein with diphtheria toxin data

SRGN (Hopkinton, Mass.) reported on a total of 23 patients now entered in an ongoing, open-label, Phase I/II trial. Four patients, after three courses at the 300 kU/kg dose, had a 53 percent mean reduction from baseline of their disease severity scores. This dose is the highest for which complete data are available; the remaining patients had a 46 percent mean reduction in scores from baseline. A 450 kU/kg dose is now being tested.

The scale used is the Psoriasis Area and Severity Index (PASI), which decreased by a mean of 32 percent after two courses (p= 0.0001) in all patients enrolled so far. ...